复发或难治性霍奇金淋巴瘤治疗方案的药物经济学评价

Review of Pharmacoeconomic Evaluation on Treatment of Relapsed or Refractory Hodgkin’s Lymphoma

目的对国外复发或难治性霍奇金淋巴瘤(relapsed/refractory Hodgkin lymphoma,RR-HL)治疗方案的药物经济学评价进行分析,以期为相关决策提供依据。方法检索中国期刊全文数据库、万方数据知识服务平台、Pubmed、EMbase等数据库,筛选出文章7篇,分析模型、成本、产出等要素。结果共纳入7项开展于美国、英国、伊朗及加拿大的研究。国内关于RR-HL的药物经济学评价尚属空白,国外多采用Markov模型。结论目前关于RR-HL治愈率较高的药物,是否具有经济学优势取决于不同国家的经济水平,我国RR-HL患者应根据经济能力选择药品,医保部门应针对罕见病适当降低对增量成本-效果比(ICER)的要求。

Objective To analyze the pharmacoeconomics evaluation of relapsed/refractory Hodgkin’s lymphoma(RR-HL)treatment in foreign countries,in order to provide evidence for related decisions.Methods CNKI,Wanfang Data Knowledge Service Platform,Pubmed,EMbase and other databases were searched,7 articles were screened out,and their model,cost,output and other elements were analyzed.Results A total of 7 studies were conducted in the United States,Britain,Iran and Canada.The pharmacoeconomic evaluation of relapsed or Refractory Hodgkin’s Lymphoma in China is still blank,and Markov model is often used in foreign countries.Conclusion At present,the economy of drugs with high cure rate of RR-HL depends on the economic level of different countries.RR-HL patients in China should choose drugs according to their economic ability,and the medical insurance department should appropriately reduce the requirements on ICER in view of rare diseases.